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In the present study, we studied the effects of metformin and its interactions with the actions of bone
morphogenetic proteins (BMPs) on ovarian steroidogenesis. It was revealed that metformin treatment
enhanced progesterone production by human granulosa KGN cells and rat primary granulosa cells
induced by forskolin and FSH, respectively. In human granulosa cells, it was found that metformin
treatment suppressed phosphorylation of Smad1/5/9 activated by BMP-15 compared with that induced
by other BMP ligands. Moreover, metformin treatment increased the expression of inhibitory Smad6, but
not of that Smad7, in human granulosa cells, while metformin had no signiﬁcant impact on the
expression levels of BMP type-I and -II receptors. Thus, the mechanism by which metformin suppresses
BMP-15-induced Smad1/5/9 phosphorylation is likely, at least in part, to be upregulation of inhibitory
Smad6 expression in granulosa cells. The results suggest the existence of functional interaction between
metformin and BMP signaling, in which metformin enhances progesterone production by down-
regulating endogenous BMP-15 activity in granulosa cells.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Metformin is an insulin-sensitizing agent and has been widely
used for patients with type II diabetes. Metformin increases insulin
sensitivity by decreasing glucose production in the liver and
increasing glucose uptake in muscle. In addition to its anti-diabetic
effects, metformin has been shown to exert beneﬁcial effects on
polycystic ovary syndrome (PCOS) and protective effects against
cardiovascular diseases and cancers [1]. PCOS, which affects
women of reproductive age, is characterized by the defect of, activin receptor-like kinase;
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Otsuka).ovulation and excess of androgens with manifesting menstrual ir-
regularity, hirsutism and infertility [2]. Patients with PCOS also
have increased risk factors for cardiovascular diseases just as shown
in the patients withmetabolic syndrome [3]. It has been considered
that the existence of insulin resistance is highly involved in the
pathogenesis of PCOS [4]. Therefore, clinical attention has been paid
to the effects of metformin, which is linked to the improvement of
insulin resistance, on changes of reproductive function in patients
with PCOS.
On the other hand, it has been demonstrated that various
growth factors expressed in the ovary play crucial and unique roles
in integrating female reproduction in autocrine and/or paracrine
fashion [5]. The growth factors, including bone morphogenetic
proteins (BMPs) and growth differentiation factors (GDFs), mutu-
ally interact with gonadotropin actions in the ovary, leading to
normal process of folliculogenesis and the following ovulation.
Among these, the BMP system in ovarian follicles can mainly
regulate the activity of FSH receptor (FSHR) signaling in granulosa
cells [5,6].
In the present study, the effect of metformin on ovarian
Fig. 1. Effects of metformin on steroidogenesis by human and rat granulosa cells. A, B) Conditioned media were collected from (A) human granulosa KGN cells and (B) rat
primary granulosa cells (GCs) treated in a serum-free condition with the indicated concentrations of metformin either alone or in combination with FSK (3 mM) for 24 h or FSH
(10 ng/ml) for 48 h, respectively, and the levels of progesterone and estradiol production were measured by CLIA and expressed as fold changes. C) Total cellular RNA was extracted
from KGN cells treated with FSK (3 mM) either alone or in combination with metformin (1 mM) in a serum-free condition for 24 h, and mRNA expression levels of steroidgenetic
genes including StAR, P450scc, 3bHSD and P450arom were determined by quantitative PCR. The expression levels of mRNA were normalized by RPL19 level and expressed as fold
changes. Results in all panels are shown as means ± SEM of data from at least three separate experiments, each performed with triplicate samples. The results were analyzed by
ANOVA. *P< 0.05 vs. control groups; and #P< 0.05 vs. the groups treated with FSK or FSH alone.
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and BMP activity were investigated by utilizing the KGN cell line
and rat primary granulosa cells. Actually, it has been recognized
that treatment of PCOS patients with metformin alleviates hyper-
androgenism and restores the menstrual cycle and ovulatory pro-
cess [7]. However, the mechanisms underlying the effects of
metformin on reproductive function and steroidogenesis have yet
to be clariﬁed. Here, it was uncovered that metformin is directly
and functionally involved in progesterone production by modu-
lating the BMP system in granulosa cells.
2. Materials and methods
2.1. Reagents and supplies
1:1 mixture of Dulbecco's Modiﬁed Eagle's Medium/Ham's F-12
medium (DMEM/F12), HEPES buffer, McCoy's 5A and Medium 199
were purchased from Invitrogen Corp. (Carlsbad, CA); 4-
androstene-3,17-dione, diethylstilbestrol (DES), 3-isobutyl-1-
methylxanthine (IBMX), ovine pituitary FSH, forskolin (FSK), and
penicillin-streptomycin were purchased from Sigma-Aldrich Co.
Ltd. (St. Louis, MO); recombinant human BMP-2, -4, -6, -7, -9 and
-15 were purchased from R&D Systems Inc. (Minneapolis, MN); and
metformin was purchased from Wako Pure Chemical Industries,
Ltd. (Osaka, Japan).
2.2. Cell preparations of KGN and rat granulosa cells
The KGN cells, originated from the human ovarian granulosa-like tumor cell line [8,9], were cultured in DMEM/F12 supple-
mented with 10%FCS and penicillin-streptomycin at 37 C in an
atmosphere of 5%CO2. Primary culture of rat granulosa cells (GCs)
was obtained from the ovaries of female Sprague-Dawley rats
(Charles River, Wilmington, MA) exposed to DES-containing cap-
sules (10 mg/tube) for 3 days by puncturing ovarian follicles with a
27-gauge needle and by ﬁltering the cell suspension (BD Falcon,
Bedford, MA) [10], and then the isolated granulosa cells were
cultured in a serum-free McCoy's 5A medium supplemented with
antibiotics at 37 C with 5%CO2 conditions. The protocol for animal
experiments (OKU-2016065) was approved by Okayama University
Institutional Animal Care and Use Committee.
2.3. Assays for estradiol and progesterone
KGN cells (1 105 viable cells/ml) were cultured in serum-free
DMEM/F12 with androstenedione (100 nM; a substrate for aro-
matase) in 12-well plates, and then treated with FSK (3 mM) either
alone or in combination with the indicated concentrations of
metformin for 24 h. Rat granulosa cells (1 105 viable cells/0.2ml)
were cultured in serum-free McCoy's 5A with androstenedione
(100 nM) in 96-well plates, and then treated with FSH (10 ng/ml)
either alone or in combinationwith the indicated concentrations of
metformin for 48 h. A range of metformin concentrations from
10 nM to 10 mM was screened, and by preliminary experiments,
1e3 mM of metformin was shown to elicit considerable changes in
steroidogenesis. On the basis of results of our earlier in vitro ex-
periments on the same culture conditions [11e15], each concen-
tration of FSK (3 mM), FSH (10 ng/ml) and BMP ligands (100 ng/ml)
Fig. 2. Effects of metformin on Smad signaling induced by BMPs in human gran-
ulosa cells. A, B) KGN cells were cultured in serum-free DMEM/F12 with indicated
concentrations of metformin for 24 h, and then stimulated with BMP-2, -4, -6, -7, -9,
and -15 (10e30 ng/ml) for 60min. The protein cell lysates were analyzed by SDS-PAGE/
immunoblotting using anti-pSmad1/5/9 antibodies. The signal intensities of pSmad1/
5/9 were normalized by those of total Smad1 in each sample and then expressed as
fold changes. C) Total cellular RNA was extracted from KGN cells treated with BMP-15
(30 ng/ml) either alone or in combination with metformin (3 mM) in a serum-free
condition for 24 h, and the mRNA level of Id-1 was determined by quantitative PCR.
Results in all panels are shown as means ± SEM of data from at least three separate
experiments, each performed with triplicate samples. The results were analyzed by
ANOVA. Values with different superscript letters are signiﬁcantly different at P < 0.05;
and *P < 0.05 vs. control groups.
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progesterone production in the culture media were analyzed using
Architect kits for estradiol and progesterone (Cayman Chemical Co.,
Ann Arbor, MI, USA) by chemiluminescent immunoassay (CLIA).
Steroid levels were undetectable (progesterone content of <10 pg/
ml and estradiol content of <15 pg/ml) in each cell-free culture
medium.2.4. Procedure of real-time RT-PCR
KGN cells (1 105 cells/ml) were treated with FSK (3 mM) either
alone or in combination with metformin (1 mM) in serum-free
DMEM/F12 in 12-well plates. After 24-h culture, total RNA was
extracted using TRI Reagent® (Cosmo Bio Co., Ltd., Tokyo, Japan)
and the yields of RNA were measured by using a NanoDrop™ One
spectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA). The
primer sets were selected from different exons of the correspond-
ing genes to eliminate PCR products arisen from chromosome DNA.
Primer pairs for the genes of steroidogenic factors and enzymes,
including steroidogenic acute regulatory protein (StAR), steroid
side-chain cleavage enzyme (P450scc), 3b-hydroxysteroid dehy-
drogenase (3bHSD), and aromatase (P450arom); BMP receptor
(BMPR) signaling molecules, including activin type-II receptor
(ActRIIA), BMP type-II receptor (BMPRII), activin receptor-like ki-
nase (ALK)-2, 3 and 6, Id-1, and Smad6 and Smad7; and a
housekeeping gene, ribosomal protein L19 (RPL19), were selected
as we reported previously [9,11e15]. The extracted RNA (0.5e1 mg)
was subjected to reverse transcription (RT) with ReverTra Ace®
(TOYOBO CO., LTD., Osaka, Japan). Quantitative real-time PCR was
performed using the LightCycler® Nano real-time PCR system(Roche Diagnostic Co., Tokyo, Japan) under the optimized annealing
conditions and ampliﬁcation efﬁciency [14]. The mRNA levels of
target genes were analyzed by the D threshold cycle (Ct) method, in
which DCt values were obtained by subtracting the Ct value of
RPL19 from that of the target. The mRNA levels of target genes
relative to RPL19 were expressed as 2-(DCt), and then the data were
expressed as the mRNA ratios of target to RPL19.
2.5. Western blots for smads
KGN cells (1 105 cells/ml) were pretreated with metformin
(3 mM) in serum-free DMEM/F12 for 24 h and subsequently stim-
ulated with various BMP ligands (10e30 ng/ml) for 1 h. In another
study, cells (1 105 cells/ml) were treated with metformin (3 mM)
in serum-free condition for 24e72 h. The cell lysates were then
collected by solubilizing cells into RIPA lysis buffer (50 ml) (Upstate
Biotechnology, Lake Placid, NY) containing 1mM Na3VO4, 1mM
NaF, 2% SDS and 4% b-mercaptoethanol. The lysates were then
subjected to SDS-PAGE/immunoblotting with antibodies against
phospho-Smad1/5/9 (pSmad1/5/9), total-Smad1 (tSmad1; Cell
Signaling Technology, Inc., Beverly, MA), Smad6 (Cell Signaling
Technology, Inc., Beverly, MA), Smad7 (R&D Systems Inc.), and actin
(Sigma-Aldrich Co. Ltd.). The integrated band intensities were
analyzed to express numerical values by the C-DiGit® Blot Scanner
System (LI-COR Biosciences, NE) and the data were shown as the
relative ratios of pSmad/tSmad or Smad/actin.
2.6. Statistics
Results are shown as means± SEM of data from at least three
independent experiments with triplicated samples. Statistical
analysis was performed by ANOVA with Fisher's protected least
signiﬁcant difference (PLSD) and the unpaired t-test (StatView 5.0
software, Abacus Concepts, Inc., Berkeley, CA). P values< 0.05 were
accepted as statistically signiﬁcant.
3. Results
We ﬁrst investigated the effects of metformin on the production
of progesterone and estradiol by human KGN cells. To examine the
effects of metformin on FSK-induced steroidogenesis in KGN cells,
the conditioned media collected following 24-h culture under the
presence or absence of metforminwere tested for CLIA. As shown in
Fig. 1A, levels of FSK (3 mM)-induced progesterone productionwere
signiﬁcantly enhanced by treatment with metformin (0.03e1 mM),
whereas metformin did not change FSK-induced estradiol pro-
duction. The same experiment was performed using primary rat
granulosa cells to see whether similar results would be obtained. As
shown in Fig. 1B, levels of FSH (10 ng/ml)-induced progesterone
production were signiﬁcantly augmented with more than 1 mM of
metformin. Since metformin treatment upregulated the FSK-
induced production of steroids, the mRNA levels of genes
involving in steroidogenesis, StAR, P450scc, 3bHSD and P450arom,
were examined by quantitative RT-PCR. As expected, metformin
(1 mM) increased the mRNA expression of StAR, P450scc and
3bHSD, but not that of P450arom, induced by FSK (3 mM) (Fig. 1C).
The BMP system that resides in the ovary plays an inhibitory role
in FSH-included progesterone production during folliculogenesis.
Therefore, involvement of BMP actions were investigated by SDS-
PAGE/immunoblotting using protein lysates derived from BMP-
treated KGN cells. As shown in Fig. 2A, the phosphorylation of
Smad1/5/9 induced by BMP-2, -4, -6, -7 or -9 (10 ng/ml) was not
affected by treatment with metformin (3 mM). However, the phos-
phorylation of Smad1/5/9 induced by BMP-15 (30 ng/ml) was
suppressed by metformin (3 mM) (Fig. 2B). In addition, the mRNA
Fig. 3. Effects of metformin on the expression of genes involved in BMP signaling. A) Total cellular RNAwas extracted from KGN cells treated with or not treated with metformin
(3 mM) in a serum-free condition for 24 h, and mRNA expression levels of receptor genes, BMPRII, ActRII, ALK-2, -3 and -6, and inhibitory Smad6 and Smad7, were determined by
quantitative PCR. Results in all panels are shown as means ± SEM of data from at least three separate experiments, each performed with triplicate samples. B) The protein cell lysates
were collected after the treatment with metformin (3 mM) for 24 he72 h in a serum-free condition and analyzed by Western blot using anti-Smad6 and anti-Smad7 antibodies. The
signal intensities of Smad6/7 were normalized by those of anti-actin antibody in each sample and then expressed as fold changes. The results were analyzed by the unpaired t-test
(A) and ANOVA (B). Values with different superscript letters are signiﬁcantly different at P < 0.05; and *P< 0.05 vs. control groups.
Fig. 4. Potential interaction of metformin and BMP-receptor signaling in modu-
lation of progesterone production by granulosa cells. In human granulosa KGN cells,
metformin was found to enhance progesterone production induced by FSH or FSK.
Metformin was also found to suppress Smad1/5/9 phosphorylation induced by BMP-15
through upregulation of inhibitory Smad6 in human KGN granulosa cells.
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quantitative PCR. Fig. 2C shows that treatment with BMP-15 (30 ng/
ml) upregulated the expression of Id-1 mRNA, which was signiﬁ-
cantly suppressed by treatment with metformin (3 mM) as shown
by Western blots.
To determine the mechanism by which metformin affects BMP
signaling in KGN cells, the effects of metformin on the expression of
genes involved in BMP-15 signaling were examined by quantitative
PCR. As shown in Fig. 3A, treatment with metformin (3 mM) did not
signiﬁcantly affect mRNA expression of the type-I or -II receptor
subunits in KGN cells, though slight increases in the expression
levels of BMPRII and ALK-2, -3 and -6 were observed. Of note,
among the inhibitory Smads, the mRNA expression of Smad6, but
not that of Smad7, was signiﬁcantly upregulated by treatment with
metformin (3 mM). To determine whether this was also detectable
at the protein levels of inhibitory Smads, Western blotting was
performed for Smad6 and Smad7. As shown in Fig. 3B, treatment
with metformin (3 mM) signiﬁcantly increased the protein expres-
sion level of Smad6, but not that of Smad7, for 24e72 h. Thus, the
results suggested that metformin acts to upregulate Smad6
expression that regulates BMP-15 activity, leading to the
enhancement of progesterone production induced by granulosa
cells induced by FSK or FSH (Fig. 4).
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In the present study, it was revealed that metformin enhanced
progesterone synthesis by granulosa cells induced by FSK or FSH,
whereas metformin had no effect on estradiol levels. The effects of
metformin are linked to the activation of hepatic and muscular
AMP-activated protein kinase (AMPK), leading to suppression of
fatty acid synthesis in the liver and increase of glucose uptake in
muscle [16,17]. It has been reported that a relatively low concen-
tration of metformin (100 nM) attenuates basal and insulin-
stimulated aromatase expression via the mitogen-activated pro-
tein kinase (MAPK) pathway in human luteinized granulosa cells
[18] and that it also inhibits FSHR activity in human granulosa KGN
cells [19]. A high concentration (10mM) of metformin has been
reported to reduce both estrogen and progesterone production via
an AMPK-dependent pathway in rat granulosa cells [20] and bovine
granulosa cells [21,22]. The effects of metformin on ovarian ste-
roidogenesis seem to be concentration-dependent. In the present
study, we utilized a medium range of metformin concentrations
(1e3 mM) that augmented FSK-induced progesterone synthesis, but
not estradiol level, by human KGN granulosa cells. It was of interest
that metformin treatment suppressed phosphorylation of Smad1/
5/9 activated by BMP-15 compared with that induced by BMP-2, -4,
-6, -7 and -9. Moreover, metformin treatment enhanced the
expression of inhibitory Smad6 in KGN cells. Thus, the mechanism
by which metformin suppresses BMP-15-induced Smad1/5/9
phosphorylation is likely, at least in part, to be upregulation of
inhibitory Smad6 expression in granulosa cells.
It is thought that the BMPs also have roles in the pathogenesis of
PCOS, although the approaches to BMP-15 and GDF-9 genes have
not yet revealed signiﬁcant relevance to the etiology of PCOS
[23,24]. The results of the present study indicated that metformin
enhanced progesterone production by suppressing intracellular
BMP-15 signaling; however, the endogenous levels of BMP-15 and
GDF-9 expression do not seem to be stable in ovaries derived from
patients with PCOS. Analysis of the expression of these factors in
PCOS provided some interesting results. For instance, it was re-
ported that GDF-9 transcription was delayed and decreased in the
growing and differentiating stages of human PCOS ovaries [25]. The
expression levels of GDF-9 and BMP-15 per oocytes were shown by
single-cell expression analysis to be higher in PCOS patients [26].
Another study showed distinct changes in the expression levels of
BMP-15 and GDF-9: GDF-9 expression level was lower and BMP-15
expression level was higher in granulosa cells from FSH-stimulated
PCOS ovaries [27]. It was also shown that GDF-9 expression levels in
cumulus cells were lower in PCOS patients [28] and that the dy-
namic changes in the expression pattern of GDF-9 and BMP-15
disappeared in oocytes from patients with PCOS [29]. Another
study also showed that the expression levels of GDF-9 and BMP-15
were impaired and delayed in the early stage of follicular devel-
opment of PCOS tissues [30].
Regarding expressional changes of BMP-15 and GDF-9 in oo-
cytes of PCOS patients treated with metformin, it was reported that
the level of BMP-15 protein in oocytes were not changed but that
the expression level of GDF-9 in oocytes was signiﬁcantly increased
by metformin treatment [31]. Besides the actions of metformin, we
previously reported that melatonin [32], androgen [11], insulin-like
growth factor (IGF)-I [12] are key factors that enable to induce
Smad6 and/or Smad7 expression. On the contrary, prolactin, so-
matostatins and incretins were suggested to be suppressors for
Smad6/7 in granulosa cells [33]. Thus, a modulatory effect on BMPR
signaling mediated by Smad6/7 seems to be crucial for integrating
ovarian steroidogenesis via the endogenous BMP activity in gran-
ulosa cells.
The speciﬁcity of the interaction between metformin and BMP-15 action, compared with the other BMP ligands, was not clariﬁed
in our study. Changes in the expressional pattern of BMP type-I and
-II receptors in KGN cells might be involved in this speciﬁcity [9].
Namely, the impact of Smad6 upregulation on Smad1/5/9 signaling
may differ among the BMP ligands depending on the abundance of
BMPR subunits expressed. The upregulation of BMPRII and/or ALK-
2, -3, and -6, though the changes were insigniﬁcant, might have
counter-regulated the enhanced expression of inhibitory Smad6,
resulting in neutralization of these mutual effects on the intensity
of BMPR signaling. In addition, the regulatory mechanism of BMPs
in KGN steroidogenesis was somewhat differed from the data ob-
tained in primary granulosa cells, which may reﬂect the charac-
teristics of KGN cells derived from neoplastic granulosa cells [9].
Further studies are necessary to conclude the detailed molecular
mechanism of metformin and its intracellular actions related to
BMPR signaling.
Collectively, the results showed that metformin augments pro-
gesterone synthesis, at least in part, by downregulating BMP-15
signaling in granulosa cells (Fig. 4). The mechanism by which
metformin impairs BMP-15-induced Smad1/5/9 phosphorylation is
likely, at least in part, to be upregulation of inhibitory Smad6 in
granulosa cells. The ﬁndings suggest the possibility that metformin
is applicable for maintenance of steroidogenesis in PCOS ovaries via
modulating endogenous BMP activity.
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